Clinical characterization of severe acute respiratory infection due to human Bocavirus 1 and respiratory syncytial virus in infants hospitalized in intensive care unit
Human bocavirus 1/HBoV1 is a parvovirus associated with acute respiratory infection. In children under 2 years of age, it presents characteristics similar to other respiratory viruses; its particularities in severe cases in the intensive care unit/SARI-ICU have not been documented. Objective: to com...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo revista |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/39160 |
| Aporte de: |
| Sumario: | Human bocavirus 1/HBoV1 is a parvovirus associated with acute respiratory infection. In children under 2 years of age, it presents characteristics similar to other respiratory viruses; its particularities in severe cases in the intensive care unit/SARI-ICU have not been documented. Objective: to compare clinical characteristics of SARI-ICU cases associated with HBoV1 and Respiratory Syncytial Virus/RSV in infants.
An observational, analytical, cross-sectional study was conducted. Children under 2 years of age without comorbidities, hospitalized for SARI-ICU of the Santísima Trinidad Children's Hospital (2021), were included. HBoV1 in respiratory secretions and serum was investigated by PCR/viral load and common pathogens included in the diagnostic panel (immunofluorescence/PCR). Clinical data from cases without co-detection of HBoV1 and RSV were compared by bivariate analysis (p<0.05).
139 cases were studied; positive 119/139(85%). RSV 70/119(59%), RSV-HBoV1 co-detection 29/119(25%), HBoV1 6/119(5%), HBoV1-Other viruses 4/119(3%), SARS-CoV-2 3 /119(2%), Influenza 1/119 (1%), Rhinovirus 1/119(1%). Other 5 /119 (4%). HBoV1 cases without co-detection: 6/39, age 7.33±4.37 months (2-12), male 3/6 (50%). Prodrome 3.83±2.86 days (1-7). Manifestations: upper airway catarrh (CVAS) 25/39(64%), respiratory distress/RDS 10/39(26%), fever 4/39(10%). Bronchiolitis 2/6(33%), pneumonia 2/6(33%), recurrent wheezing 1/6(17%), septic shock 1/6(17%). Hospitalization days 15±7.2(6-22), ventilation days 10.3±7.5(3-21), maximum oxygenation index/MIO 18(10-18). White blood cells 15,628±5,693 (8,500-22,490), CRP 11.8±10.4 (1.2-21.5). No deceased. RSV cases without co-detection: 70/101 Age 5±4 (0-21) CVAS 61/70(87%), RDS 33/70(47%), Manifestations: fever 6/70(9%). Bronchiolitis 57/70(81%), recurrent wheezing 12/70(17%), whooping syndrome 1/70(1%). IOM 24 (5.5-24). One passed away. There were no significant differences between the two groups analyzed.
Viral identification in our series was high (85%), with a 33% prevalence of HBoV1 during 2021. In infants with severe acute respiratory infection in intensive care, their clinical presentation was similar to RSV cases. No deaths associated with this new respiratory pathogen was notified. |
|---|